AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

[HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their ...

As the telecoms industry hurtles towards the digital world, demand is already growing for emerging bandwidth-intensive applications and services such as artificial intelligence (AI). Telecoms ...

AstraZeneca's financial results remain strong AstraZeneca's shares fell off a cliff late last year when it announced the arrest of some of its executives in China, including Leon Wang, the ...

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year. Still, some companies are performing ...

AstraZeneca's financial results were excellent last year despite a poor stock-market performance. The company faces some near-term headwinds, but this won't derail its long-term prospects.